Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CP 001

Next Previous
Search
Drug Profile

CP 001

Alternative Names: CP-001

Latest Information Update: 07 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Academic Medical Center; Caelus Health; Wageningen University
  • Developer Caelus Health; Johnson & Johnson Innovation
  • Class Antihyperglycaemics; Bacteria
  • Mechanism of Action Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Insulin resistance; Type 2 diabetes mellitus

Most Recent Events

  • 07 Dec 2022 Discontinued - Phase-II for Type 2 diabetes mellitus in Netherlands (PO)
  • 21 Oct 2020 Caelus Health pans a clinical trial for Type 2 diabetes mellitus in H1 2021 (Caelus Health pipeline, October 2020)
  • 09 Apr 2020 Phase-I development is ongoing Insulin resistance and Type-2 diabetes mellitus (Prevention) in Netherlands (PO) (Caelus Health pipeline, April 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top